{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T19:10:38Z","timestamp":1782587438865,"version":"3.54.5"},"reference-count":21,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2021,2,10]],"date-time":"2021-02-10T00:00:00Z","timestamp":1612915200000},"content-version":"vor","delay-in-days":2293,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/3.0\/"}],"funder":[{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2014,11,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>We investigated the safety, tolerability, pharmacokinetics and pharmacodynamics of evacetrapib.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Healthy volunteers received multiple daily doses of evacetrapib (10\u2013600 mg) administered for up to 15 days in a placebo-controlled study.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Key findings<\/jats:title>\n                  <jats:p>Mean peak plasma concentrations of evacetrapib occurred at 4\u20136 h and terminal half-life ranged 24\u201344 h. Steady state was achieved at approximately 10 days; all subjects had undetectable levels of evacetrapib 3 weeks after their last dose. The trough inhibition of cholesteryl ester transfer protein (CETP) activity was 65 and 84% at 100 and 300 mg, respectively. At the highest dose (600 mg), evacetrapib significantly inhibited CETP activity (91%), increased HDL-C (87%) and apo AI (42%), and decreased LDL-C (29%) and apo B (26%) relative to placebo. For the highest dose tested, levels of evacetrapib, CETP activity, CETP mass, HDL-C and LDL-C returned to levels at or near baseline after a 2-week washout period. Evacetrapib at the highest dose tested did not produce any significant effect on 24-h ambulatory systolic or diastolic blood pressure.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Multiple doses of evacetrapib potently inhibited CETP activity, leading to substantial elevations in HDL-C and lowering of LDL-C. Evacetrapib was devoid of clinically relevant effects on blood pressure and mineralocorticoid levels.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1111\/jphp.12287","type":"journal-article","created":{"date-parts":[[2014,6,24]],"date-time":"2014-06-24T16:13:43Z","timestamp":1403626423000},"page":"1576-1585","source":"Crossref","is-referenced-by-count":35,"title":["Effects of the cholesteryl ester transfer protein inhibitor evacetrapib on lipoproteins, apolipoproteins and 24-h ambulatory blood pressure in healthy adults"],"prefix":"10.1093","volume":"66","author":[{"given":"Jeffrey G","family":"Suico","sequence":"first","affiliation":[{"name":"Lilly Research Laboratories, Eli Lilly and Company , Indianapolis, IN,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming-Dauh","family":"Wang","sequence":"additional","affiliation":[{"name":"Lilly Research Laboratories, Eli Lilly and Company , Indianapolis, IN,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stuart","family":"Friedrich","sequence":"additional","affiliation":[{"name":"Lilly Research Laboratories, Eli Lilly and Company , Indianapolis, IN,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellen A","family":"Cannady","sequence":"additional","affiliation":[{"name":"Lilly Research Laboratories, Eli Lilly and Company , Indianapolis, IN,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher S","family":"Konkoy","sequence":"additional","affiliation":[{"name":"Lilly Research Laboratories, Eli Lilly and Company , Indianapolis, IN,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giacomo","family":"Ruotolo","sequence":"additional","affiliation":[{"name":"Lilly Research Laboratories, Eli Lilly and Company , Indianapolis, IN,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn A","family":"Krueger","sequence":"additional","affiliation":[{"name":"Lilly Research Laboratories, Eli Lilly and Company , Indianapolis, IN,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2014,11,1]]},"reference":[{"key":"2024103109154661500_jphp12287-cit-0001","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/0002-9343(77)90874-9","article-title":"High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study","volume":"62","author":"Gordon","year":"1977","journal-title":"Am J Med"},{"key":"2024103109154661500_jphp12287-cit-0002","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.jacc.2007.07.086","article-title":"Clinical significance of high-density lipoprotein cholesterol in patients with low low-density lipoprotein cholesterol","volume":"51","author":"deGoma","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"2024103109154661500_jphp12287-cit-0003","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1007\/s11886-012-0252-3","article-title":"Evacetrapib","volume":"14","author":"Nicholls","year":"2012","journal-title":"Curr Cardiol Rep"},{"key":"2024103109154661500_jphp12287-cit-0004","doi-asserted-by":"crossref","first-page":"2406","DOI":"10.1056\/NEJMoa1009744","article-title":"Safety of anacetrapib in patients with or at high risk for coronary heart disease","volume":"363","author":"Cannon","year":"2010","journal-title":"N Engl J Med"},{"key":"2024103109154661500_jphp12287-cit-0005","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1056\/NEJMoa0706628","article-title":"Effects of torcetrapib in patients at high risk for coronary events","volume":"357","author":"Barter","year":"2007","journal-title":"N Engl J Med"},{"key":"2024103109154661500_jphp12287-cit-0006","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1038\/bjp.2008.229","article-title":"Torcetrapib-induced blood pressure elevation is independent of CETP inhibition and is accompanied by increased circulating levels of aldosterone","volume":"154","author":"Forrest","year":"2008","journal-title":"Br J Pharmacol"},{"key":"2024103109154661500_jphp12287-cit-0007","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1194\/jlr.M018069","article-title":"Evacetrapib is a novel, potent, and selective inhibitor of cholesteryl ester transfer protein that elevates HDL cholesterol without inducing aldosterone or increasing blood pressure","volume":"52","author":"Cao","year":"2011","journal-title":"J Lipid Res"},{"key":"2024103109154661500_jphp12287-cit-0008","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1210\/en.2008-1512","article-title":"Torcetrapib induces aldosterone and cortisol production by an intracellular calcium-mediated mechanism independently of cholesteryl ester transfer protein (CETP) inhibition","volume":"150","author":"Hu","year":"2009","journal-title":"Endocrinology"},{"key":"2024103109154661500_jphp12287-cit-0009","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1056\/NEJMoa1206797","article-title":"Effects of dalcetrapib in patients with a recent acute coronary syndrome","volume":"367","author":"Schwartz","year":"2012","journal-title":"N Engl J Med"},{"key":"2024103109154661500_jphp12287-cit-0010","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1001\/jama.2011.1649","article-title":"Effects of the CETP inhibitor evacetrapib administered as monotherapy or in combination with statins on HDL and LDL cholesterol: a randomized controlled trial","volume":"306","author":"Nicholls","year":"2011","journal-title":"JAMA"},{"key":"2024103109154661500_jphp12287-cit-0011","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1016\/j.bbadis.2009.10.017","article-title":"The role of 11\u03b2-hydroxysteroid dehydrogenase type 2 in human hypertension","volume":"1802","author":"Ferrari","year":"2010","journal-title":"Biochim Biophys Acta"},{"key":"2024103109154661500_jphp12287-cit-0012","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1023\/A:1026451721686","article-title":"Confidence interval criteria for assessment of dose proportionality","volume":"17","author":"Smith","year":"2000","journal-title":"Pharm Res"},{"key":"2024103109154661500_jphp12287-cit-0013","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1038\/clpt.2008.109","article-title":"Multiple-dose pharmacodynamics and pharmacokinetics of anacetrapib, a potent cholesteryl ester transfer protein (CETP) inhibitor, in healthy subjects","volume":"84","author":"Krishna","year":"2008","journal-title":"Clin Pharmacol Ther"},{"key":"2024103109154661500_jphp12287-cit-0014","doi-asserted-by":"crossref","first-page":"e94","DOI":"10.1038\/psp.2013.70","article-title":"The pharmacokinetics and pharmacokinetic\/pharmacodynamic relationships of evacetrapib administered as monotherapy or in combination with statins","volume":"3","author":"Friedrich","year":"2014","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"2024103109154661500_jphp12287-cit-0015","doi-asserted-by":"crossref","first-page":"76\u201383","DOI":"10.1016\/j.amjcard.2013.08.041","article-title":"Evaluation of lipids, drug concentration, and safety parameters following cessation of treatment with the cholesteryl ester transfer protein inhibitor anacetrapib in patients with or at high risk for coronary heart disease","volume":"113","author":"Gotto","year":"2014","journal-title":"Am J Cardiol"},{"key":"2024103109154661500_jphp12287-cit-0016","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1161\/01.ATV.0000161928.16334.dd","article-title":"Effects of cholesteryl ester transfer protein inhibition on high-density lipoprotein subspecies, apolipoprotein A-I metabolism, and fecal sterol excretion","volume":"25","author":"Brousseau","year":"2005","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2024103109154661500_jphp12287-cit-0017","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1172\/JCI116750","article-title":"Delayed catabolism of high density lipoprotein apolipoproteins A-I and A-II in human cholesteryl ester transfer protein deficiency","volume":"92","author":"Ikewaki","year":"1993","journal-title":"J Clin Invest"},{"issue":"10 Suppl.","key":"2024103109154661500_jphp12287-cit-0018","doi-asserted-by":"crossref","first-page":"39E","DOI":"10.1016\/j.amjcard.2009.09.018","article-title":"The effects of cholesterol ester transfer protein inhibition on cholesterol efflux","volume":"104","author":"Tall","year":"2009","journal-title":"Am J Cardiol"},{"key":"2024103109154661500_jphp12287-cit-0019","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1177\/1074248413510784","article-title":"Evacetrapib at a supratherapeutic steady-state concentration does not prolong QT in a thorough QT\/QTc study in healthy subjects","volume":"19","author":"Suico","year":"2014","journal-title":"J Cardiovasc Pharmacol Ther"},{"key":"2024103109154661500_jphp12287-cit-0020","doi-asserted-by":"crossref","first-page":"491","DOI":"10.2165\/11599310-000000000-00000","article-title":"On- and off-target pharmacology of torcetrapib: current understanding and implications for the structure activity relationships (SAR), discovery and development of cholesteryl ester-transfer protein (CETP) inhibitors","volume":"72","author":"Johns","year":"2012","journal-title":"Drugs"},{"key":"2024103109154661500_jphp12287-cit-0021","first-page":"410","article-title":"A novel method for analysis of nuclear receptor function at natural promoters: peroxisome proliferator-activated receptor gamma agonist actions on aP2 gene expression detected using branched DNA messenger RNA quantitation","volume":"13","author":"Burris","year":"1999","journal-title":"Mol Endocrinol"}],"container-title":["Journal of Pharmacy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjphp.12287","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jphp.12287","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/jphp.12287","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/jpp\/article-pdf\/66\/11\/1576\/60252056\/jphp12287.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jpp\/article-pdf\/66\/11\/1576\/60252056\/jphp12287.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,31]],"date-time":"2024-10-31T09:20:58Z","timestamp":1730366458000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jpp\/article\/66\/11\/1576\/6128088"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,11,1]]},"references-count":21,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2014,11,1]]},"published-print":{"date-parts":[[2014,11,1]]}},"URL":"https:\/\/doi.org\/10.1111\/jphp.12287","relation":{},"ISSN":["2042-7158","0022-3573"],"issn-type":[{"value":"2042-7158","type":"electronic"},{"value":"0022-3573","type":"print"}],"subject":[],"published-other":{"date-parts":[[2014,11]]},"published":{"date-parts":[[2014,11,1]]}}}